Literature DB >> 6459224

Cefoperazone: A review of its in vitro antimicrobial activity, pharmacological properties and therapeutic efficacy.

R N Brogden, A Carmine, R C Heel, P A Morley, T M Speight, G S Avery.   

Abstract

Cefoperazone is a new 'third generation' semisynthetic injectable cephalosporin. It has a broad spectrum of antibacterial activity which includes Pseudomonas aeruginosa (unlike older cephalosporins), along with the Enterobacteriaceae and other Gram-negative bacteria, Gram-positive bacteria and anaerobic bacteria. Unlike other cephalosporins, cefoperazone is excreted to a considerable extent by extrarenal mechanisms. Given by intravenous or intramuscular injection, cefoperazone is effective against a wide variety of infections caused by Gram-negative or Gram-positive aerobes, including infections of the biliary tract, and in many anaerobic infections. It is generally well tolerated, diarrhoea and skin rashes being the most frequently reported side effects.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6459224     DOI: 10.2165/00003495-198122060-00002

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  94 in total

1.  Antabuse effect with cephalosporins.

Authors:  D S Reeves; A J Davies
Journal:  Lancet       Date:  1980-09-06       Impact factor: 79.321

2.  Activity of beta-lactamase produced by Bacteroides fragilis against newly introduced cephalosporins.

Authors:  K Sato; M Inoue; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1980-04       Impact factor: 5.191

3.  Microbiological studies on cefoperazone.

Authors:  F H Kayser
Journal:  Clin Ther       Date:  1980       Impact factor: 3.393

4.  A comparative study of the activity of cefamandole and other cephalosporins and analysis of the beta-lactamase stability and synergy of cefamandole with aminoglycosides.

Authors:  K P Fu; H C Neu
Journal:  J Infect Dis       Date:  1978-05       Impact factor: 5.226

5.  Cefotaxime kinetics after intravenous and intramuscular injection of single and multiple doses.

Authors:  H C Neu; P Aswapokee; K P Fu; I Ho; C Matthijssen
Journal:  Clin Pharmacol Ther       Date:  1980-05       Impact factor: 6.875

6.  Disulfiram-like reaction associated with a parenteral cephalosporin.

Authors:  T S Foster; C L Raehl; H D Wilson
Journal:  Am J Hosp Pharm       Date:  1980-06

7.  Effect of inoculum size and beta-lactamase production on in vitro activity of new cephalosporins against Haemophilus species.

Authors:  R R Bulger; J A Washington
Journal:  Antimicrob Agents Chemother       Date:  1980-03       Impact factor: 5.191

8.  Clinical experience with cefoperazone in biliary tract infections.

Authors:  K Mashimo
Journal:  Drugs       Date:  1981       Impact factor: 9.546

9.  [Pharmacokinetic study of a cephalosporin, cefoperazone, in liver failure].

Authors:  J Belaieff; B Cochet; A F Allaz; M Rudhardt; L Balant; J Fabre
Journal:  Schweiz Med Wochenschr       Date:  1981-04-04

10.  [Results of application of cefoperazone to pediatric infections (author's transl)].

Authors:  S Furukawa; T Okada; F Hirao
Journal:  Jpn J Antibiot       Date:  1980-09
View more
  20 in total

Review 1.  Pharmacological properties of cephalosporins.

Authors:  W Christ
Journal:  Infection       Date:  1991       Impact factor: 3.553

2.  Modulation of the intestinal flora of mice by parenteral treatment with broad-spectrum cephalosporins.

Authors:  M L van Ogtrop; H F Guiot; H Mattie; R van Furth
Journal:  Antimicrob Agents Chemother       Date:  1991-05       Impact factor: 5.191

3.  In vitro antimicrobial spectrum, occurrence of synergy, and recommendations for dilution susceptibility testing concentrations of the cefoperazone-sulbactam combination.

Authors:  R N Jones; A L Barry; R R Packer; W W Gregory; C Thornsberry
Journal:  J Clin Microbiol       Date:  1987-09       Impact factor: 5.948

4.  Pharmacokinetic properties of the newer cephalosporins. A valid basis for drug selection?

Authors:  J T Noble; M Barza
Journal:  Drugs       Date:  1985-09       Impact factor: 9.546

Review 5.  Antibiotic therapy in aging patients.

Authors:  S R Norrby
Journal:  Bull N Y Acad Med       Date:  1987 Jul-Aug

6.  Toxic and adverse reactions encountered with new beta-lactam antibiotics.

Authors:  M F Parry
Journal:  Bull N Y Acad Med       Date:  1984-05

Review 7.  Side effects of cephalosporins.

Authors:  S R Norrby
Journal:  Drugs       Date:  1987       Impact factor: 9.546

8.  Antimicrobial activity and other in vitro properties of cefoperazone A, the principal metabolite of cefoperazone sodium.

Authors:  R N Jones; A L Barry
Journal:  Antimicrob Agents Chemother       Date:  1983-08       Impact factor: 5.191

9.  Susceptibility of anaerobic bacteria from several French hospitals to three major antibiotics.

Authors:  L Dubreuil; J Devos; C Neut; C Romond
Journal:  Antimicrob Agents Chemother       Date:  1984-06       Impact factor: 5.191

10.  Pharmacokinetics of cefoperazone in full-term and premature neonates.

Authors:  W N Rosenfeld; H E Evans; R Batheja; R C Jhaveri; K Vohra; A J Khan
Journal:  Antimicrob Agents Chemother       Date:  1983-06       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.